Printer Friendly

CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE

 CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE
 VANCOUVER, British Columbia, Jan. 13 /PRNewswire/ -- The following was released today by canguard Health Technologies Inc.:
 Canguard Health Technologies Inc. (Vancouver: CGD) reports that the Canguard Group was extremely disappointed yesterday to learn from the news release of Deprenyl Research Ltd. (NASDAQ: DEPFL; Toronto: DEP) that Deprenyl has distorted the purpose of the agreement reached with the Canguard Group. The public was misled when it was advised that Deprenyl has satisfied it's claims against the Canguard Group and that the matter may be over. As a result, one news wire service incorrectly reported that Canguard was effectively blocked from making or marketing a drug similar to the Deprenyl product. The attempt by Deprenyl to discredit the Canguard Group and suppress legitimate competition will fail because it is not based on fact. The Canguard Group does not and will not infringe the Chinoin patent and will market its product, PARKINYL, worldwide as planned.
 The Canguard Group agreed to suspend legal proceedings against Deprenyl and Chinoin on the condition that they would cooperate to pursue a timely, out-of-court resolution to the outstanding claims of all parties. It is false that the Canguard Group asked for more time to address Deprenyl's injunction hearing. The Canguard Group agreed to limit certain activities only as an act of good will on the basis that this was voluntary, short term, and without prejudice to its business or legal remedies.
 Selegiline hydrochloride (deprenyl) is not a new substance. Under the Patent Act, Deprenyl and Chinoin must prove the Canguard Group is infringing. Deprenyl and Chinoin have presented no evidence of infringement because none exists.
 Deprenyl has implied that Canguard will not market PARKINYL in Canada. This is not true. Canguard has legitimate rights to enter the market with its product and will do so in Canada and worldwide, on schedule. Canguard will ensure its rights are enforced.
 -0- 1/13/92
 /CONTACT: John B. Armstrong of Canguard, 604-682-1777/
 (CGD. DEP DEPFL) CO: Canguard Health Technologies Inc. ST: British Columbia IN: SU:


EH -- LA004 -- 8928 01/13/92 08:34 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1992
Words:350
Previous Article:ELECTRO RENT POSTS 33 PERCENT IMPROVEMENT IN SECOND QUARTER NET INCOME PER SHARE ON HIGHER REVENUES FOR THE PERIOD
Next Article:SCT AWARDED TWO MULTI-YEAR, MULTI-MILLION DOLLAR OUTSOURCING CONTRACTS
Topics:


Related Articles
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO COMMENTS ON DEPRENYL RESEARCH LTD. PRESS RELEASE
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO LAWSUIT ANNOUNCED IN PRESS ON DEC. 3
CANGUARD HEALTH TECHNOLOGIES ANNOUNCES LAWSUIT UPDATE
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
CANGUARD HEALTH TECHNOLOGIES ADJOURNMENT AGREEMENT
CANGUARD ANNOUNCES PRIVATE PLACEMENT AND APPOINTMENT OF FISCAL AGENT
CANGUARD AND DEPRENYL RESEARCH LAWSUIT ADJOURNED TODAY; NO RESTRICTIONS IMPOSED ON CANGUARD
CANGUARD SERVES NOTICE OF MOTION, FINAL AFFIDAVITS ON DEPRENYL RESEARCH; ANNOUNCES NEW BUSINESS DEVELOPMENTS
DEPRENYL RESEARCH ELECTS MARTIN BARKIN PRESIDENT, CHIEF OPERATING OFFICER AND DIRECTOR
CANGUARD HEALTH TECHNOLOGIES INC. RELEASES DETAILS OF ANNUAL REPORT TO SHAREHOLDERS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters